Genospectra Inc. is merging with Panomics Inc., a leading provider of life sciences research reagents for transcription regulation, cell signalling and signal transduction.

Dr. Frank Witney, Genospectra's CEO said, "Genospectra and Panomics have long discussed the remarkable synergy between our two businesses. We are impressed with the way that Panomics has quickly established a broad portfolio of innovative products for proteomics analysis and live-cell assays. We are convinced that when united with our parallel quantitative biology (PQB) initiative, the combined entity will be well positioned for rapid growth since it will serve a wide range of customers in both academic and for-profit end markets."

Panomics offers a wide array of products for life sciences and drug discovery research, including multiplex assays for the global analysis of transcriptional regulation and cell signalling. By combining this portfolio with Genospectra's innovative products and technologies for PQB, the new company will provide an integrated pipeline of products in the functional biology and drug discovery space, claims the company release.

The mission of the combined entity is to establish world-wide leadership with PQB products for basic life science research and critical applications such as cell signalling, RNAi-mediated gene silencing and high performance assays, clinical biomarker discovery and predictive toxicology.

With plans to launch a series of innovative products to study FFPE and blood biomarkers, protein-protein interactions, cell signalling and gene silencing, the new company has already established targeted goals.

The companies will be merged under the name Panomics.

Genospectra is a privately-held life science company focused on parallel quantitative biology (PQB) to develop novel cell-based assays and tools that enable the multiplex measurement of molecular events, such as intracellular pathway analysis, in a quantitative and scalable manner. Genospectra has grown rapidly on the merits of QuantiGene and QuantiGene Plex, flagship product lines powered by the proprietary bDNA technology for gene expression analysis in cell-based assays.